Last reviewed · How we verify
NCT06574412
Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.
Phase 2 trial testing cardonilizumab combined with renvastinib in Resectable Clear Cell Carcinoma of the Kidney in 30 participants. Not yet recruiting.
31 August 2027
Quick facts
| Lead sponsor | The First Hospital of Jilin University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2024 |
| Primary completion | 31 August 2027 |
| Estimated completion | 1 September 2027 |
Drugs / interventions tested
- cardonilizumab combined with renvastinib — full drug profile →
Conditions studied
- Resectable Clear Cell Carcinoma of the Kidney — all drugs for Resectable Clear Cell Carcinoma of the Kidney →
Sponsor
The First Hospital of Jilin University
Who can join
Adults 18 to 75, any sex, with Resectable Clear Cell Carcinoma of the Kidney. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, single-center, phase II clinical study. The main purpose is to evaluate the perioperative efficacy and safety of cardenilimab combined with lenvatinib in patients with resectable clear cell renal cell carcinoma. This study included a screening period, a treatment period, and a follow-up period. After completing the examination and assessment during the screening period, qualified subjects will enter the study treatment period after signing the informed consent form. Subjects should receive induction therapy and maintenance therapy in accordance with the protocol until there is disease progression on imaging as judged by the investigator based on RECIST 1.1 standards, intolerable toxicity, or the subject voluntarily requests to terminate study treatment or withdraws information. Agree, or the researcher determines that treatment needs to be terminated. (1) Primary research endpoint: Objective response rate (ORR) of primary tumor according to RECIST 1.1 criteria (2) Secondary research endpoint: 1. According to RECIST 1.1, as assessed by the investigator: (1) Progression-free survival (Progress Free Survival, PFS); (2) Overall survival (OS); 2. Type, incidence and severity of adverse events (AE) and serious adverse events (SAE) assessed in accordance with NCI-CTCAE 5.0 . 3. Pathological response rate (MPR), R0 resection rate 4. Based on Quality of Life QoL score.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of Systemic Therapy in Localized Renal Cell Carcinoma: Where Do We Stand and Where Are We Heading?
Raghavan D, Gibatova V, Vojjala N, Moka N, et al · · 2025 · cited 2× · PMID 40427152 · DOI 10.3390/cancers17101656
Verify or expand the search:
- PubMed search for NCT06574412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Hospital of Jilin University trials
Trials by the same sponsor.
- NCT07308340 — Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT · not yet recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
- NCT07440368 — Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness · not yet recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06574412 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Jilin University
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06574412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing